Corrigendum: Salvinorin A, a kappa-opioid receptor agonist hallucinogen: pharmacology and potential template for novel pharmacotherapeutic agents in neuropsychiatric disorders
- Laboratory on the Biology of Addictive Diseases, The Rockefeller University, New York, NY, USA
by Butelman, E. R., and Kreek, M. J. (2015) Front. Pharmacol. 6:190. doi: 10.3389/fphar.2015.00190
Reason for Corrigendum:
In the original review, we placed an incorrect citation in the following sentence:
“Also, salvinorin A can act as a “punisher” to self-administration of cocaine or a short-acting MOPr agonist in primates (when given contingently; Whitfield et al., 2015).”
The correct sentence and citation are as follows:
“Also, salvinorin A can act as a “punisher” to self-administration of cocaine or a short-acting MOPr agonist in primates (when given contingently; Freeman et al., 2014).”
The authors apologize for the mistake. This error does not change the scientific conclusions of the review.
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Freeman, K. B., Naylor, J. E., Prisinzano, T. E., and Woolverton, W. L. (2014). Assessment of the kappa opioid agonist, salvinorin A, as a punisher of drug self-administration in monkeys. Psychopharmacology (Berl.) 231, 2751–2758. doi: 10.1007/s00213-014-3436-2
Keywords: kappa-opioid receptor, dynorphins, salvinorin A, Salvia divinorum, depression, addiction
Citation: Butelman ER and Kreek MJ (2015) Corrigendum: Salvinorin A, a kappa-opioid receptor agonist hallucinogen: pharmacology and potential template for novel pharmacotherapeutic agents in neuropsychiatric disorders. Front. Pharmacol. 6:285. doi: 10.3389/fphar.2015.00285
Received: 16 November 2015; Accepted: 16 November 2015;
Published: 30 November 2015.
Edited and reviewed by: George Panagis, University of Crete, Greece
Copyright © 2015 Butelman and Kreek. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Eduardo R. Butelman, email@example.com